Title: Why Oncology Clinical Pathways Matter for Pharma: Market Access, Value, and Strategy
Subtitle: How pharmaceutical companies can align with clinical pathway economics to improve access, adoption, and outcomes
Byline: Gordon Kuntz, Kuntz Consulting
For pharmaceutical companies, success in oncology is no longer driven by clinical efficacy alone. Even the most innovative therapies must navigate a complex ecosystem shaped by cost pressures, payer expectations, and value-based care. At the center of this ecosystem are oncology clinical pathways.
Clinical pathways are not just clinical tools. They are powerful business levers that directly influence which therapies are used, reimbursed, and scaled across oncology practices.
The Strategic Role of Clinical Pathways in Pharma
Clinical pathways guide treatment decisions at the exact moment therapies are selected. This makes them one of the most influential forces in determining product utilization.
For pharma, this means pathway inclusion can significantly impact:
- Market access
- Speed of adoption
- Competitive positioning
- Long-term revenue potential
Therapies that are not aligned with pathways often face slower uptake, additional administrative barriers, or reimbursement challenges.
Understanding the Business Drivers Behind Pathways
To engage effectively, pharma must understand what pathways are designed to optimize. Pathway developers evaluate therapies based on three primary factors:
- Clinical efficacy
- Safety and toxicity
- Cost, when other factors are equal
Importantly, cost is not the primary driver. However, it becomes a critical differentiator in crowded therapeutic classes where multiple options show similar outcomes.
How Pathways Shape Market Access
Payer Influence and Reimbursement
Payers use pathways to promote high-value care while managing costs. Therapies that align with payer pathways may benefit from:
- Faster prior authorization
- Fewer reimbursement barriers
- Preferred positioning
In contrast, off-pathway therapies may require additional documentation or appeals, slowing adoption.
Provider Adoption and Workflow Integration
Oncology practices rely on pathways to standardize care and improve efficiency. Therapies embedded within these systems are more likely to be selected during routine clinical workflows.
Value-Based Care Alignment
As more oncology practices enter value-based arrangements, pathways become essential tools for managing utilization and cost.
This creates a clear expectation: therapies must demonstrate not only clinical benefit but also economic value.
Key Opportunities for Pharma
Pharmaceutical companies that understand the business of pathways can take a more proactive approach.
1. Align Evidence Generation with Pathway Needs
Pathways rely on published, credible evidence. Generating strong comparative data and real-world evidence can improve pathway positioning.
2. Demonstrate Total Value, Not Just Price
Pathways reward therapies that reduce overall cost of care by avoiding ineffective treatments or minimizing side effects.
3. Engage Early with Pathway Stakeholders
Understanding how disease committees evaluate therapies allows pharma to better anticipate decision-making criteria.
4. Support Provider Workflows
Therapies that integrate smoothly into pathway-driven workflows are more likely to be adopted at scale.
The Risk of Ignoring Pathways
Failing to account for pathways can lead to:
- Delayed or limited adoption
- Increased reimbursement friction
- Reduced competitiveness in crowded markets
In a landscape where pathways influence both clinical and financial decisions, they are no longer optional considerations for pharma strategy.
Why Clinical Pathways Congress Is Critical for Pharma
The Clinical Pathways Congress is one of the few forums where pharma, payers, and providers come together to address these challenges directly.
For pharmaceutical leaders, attending Clinical Pathways Congress offers:
- Insight into how pathway decisions are made
- Direct engagement with pathway developers and oncology leaders
- Strategies for improving market access in a value-driven environment
- A clearer understanding of payer and provider expectations
As pathways continue to shape oncology care, staying informed is essential for maintaining competitive advantage.
Event Details
Event: Clinical Pathways Congress
Dates: November 10-11, 2026
Location: Four Seasons, Boston, MA
Event Website: https://www.hmpglobalevents.com/cpc
Registration: https://tinyurl.com/3z22pvsk
Business Session Information
- From Evidence to Action: Building Pathways That Drive Value
Date/Time: November 10, 2026. 9:50 AM – 10:35 AM
Summary: This session explores how organizations can translate clinical evidence into actionable pathways that deliver measurable value. Learn strategies for balancing efficacy, safety, and cost, while defining and tracking value-based metrics that resonate with clinicians, administrators, and payers. - The Business of Pathways: Aligning Clinical Innovation with Financial Sustainability
Date/Time: November 10, 2026. 11:00 AM – 11:45 AM
Summary: Clinical pathways play a critical role in both care standardization and financial performance. This session examines how organizations can align clinical innovation with fiscal responsibility, covering budgeting, reimbursement considerations, stakeholder buy-in, and demonstrating return on investment. - Pharma and Pathways: Redefining Collaboration for Value-Based Success
Date/Time: November 11, 2026. 9:15 AM – 10:00 AM
As pathways increasingly influence treatment decisions, collaboration between pharma and providers is evolving. This session explores emerging partnership models that support evidence-based care, transparency, and value-based outcomes—while aligning clinical goals with business realities. - Policy Pathways: Navigating Regulation, Reimbursement, and Accountability
Date/Time: November 11, 2026. 10:30 AM – 11:15 AM
This session examines how evolving healthcare policy and regulatory frameworks shape clinical pathway design and adoption. Attendees will gain insight into navigating reimbursement models, compliance requirements, and accountability measures—while maintaining flexibility to support innovation and value-based care. - The Economics of Care: Contracting, Incentives, and Shared Savings
Date/Time: November 11, 2026. 2:15 PM – 3:30 PM
This session focuses on the financial mechanisms driving pathway innovation. Learn how contracting strategies, incentive structures, and shared savings models can support pathway adoption, align stakeholders, and advance value-based care across healthcare systems.
Reference
A practical guide to oncology clinical pathways. Journal of Clinical Pathways. 2025.
About the Author
Gordon’s expertise includes over 20 years working in the cancer space for a variety of companies directly and as a consultant. Through his broad experience, Gordon has developed a unique understanding of the entire cancer care ecosystem.
Since 2004, Gordon has worked in the business of oncology for a variety of organizations, including US Oncology, ION Solutions/AmerisourceBergen, Via Oncology/Elsevier, a large NCI Cancer Center, and multiple drug companies. He is a though leader and subject matter expert regarding payer relations/payer programs, value-based care, practice economics, and oncology clinical pathways. A member of the editorial board of the Journal of Clinical Pathways, he has contributed numerous articles and has moderated the Oncology Clinical Pathways Congress since 2019. Gordon hosts the video podcast series entitled Oncology Innovations and is a frequent speaker on the cancer care ecosystem and the business of oncology.
Gordon currently consults with pharma manufacturers and others, providing strategic advice on issues that impact and influence pathways, quality and value programs, practice economics, and payer perspectives.